Overactive bladder associated with benign prostatic hyperplasia
Conditions
Interventions
Fesoterodine 4mg~8mg/day
Sponsors
Dept. of Urology, Kyoto University Graduate School of Medicine
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1) Obtaining of written informed consent 2) Adult male, aged≥50 3) Prostate volume≥20ml 4) Before administration of alpha-1 blockers, IPSS≥8 and QOL score≥2 5) After 4-week of more administraion of alpha-1 blockers, OABSS≥3 and OABSS third question≥2
Exclusion criteria
Exclusion criteria: 1) Post-void residual≥50ml 2) Urinary retention 3) Prostate cancer, neurogenic bladder, urethral stricture, chronic prostatitis, urinary infection, urinary tract calculi, interstitial cystitis 4) Patients who are contraindicated for fesoterodine administration 5) Within 2 weeks before entry, administration of contraindicated agents or treatments
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of maximal bladder capacity and detrusor pressure on voiding by fesoterodine administration | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Changes of other parameters of urodynamic studies 2) Changes of parameters of questionnaires 3) Changes of parameters of frequency-volume charts 4) Safety 5) Ratio of increase of fesoterodine dose | — |
Countries
Japan
Contacts
Public ContactMayumi Yagi
Kyoto University Graduate School of Medicine Urology
Outcome results
None listed